For Patients.
We believe that Minimal Residual Disease (MRD) monitoring can be an important predictor of disease progression and relapse after treatment and provide peace of mind for patients. We believe that designing a highly sensitive test that does not require bone marrow aspiration will make it more accessible. That’s why we are developing EasyM.
We believe that Minimal Residual Disease (MRD) monitoring can be an important predictor of disease progression and relapse after treatment and provide peace of mind for patients. We believe that designing a highly sensitive test that does not require bone marrow aspiration will make it more accessible. That’s why we are developing EasyM.
Overview.
Standards for MRD testing and standards of care are still emerging. EasyMTM is not yet certified for clinical use – at this point it is being used in clinical trials and research studies. If you want to see more widespread use of MRD testing for Multiple Myeloma you can:
- Talk to you doctor
- Explore clinical trials for myeloma drugs and consider enrolling in one that uses EasyM or another MRD technique
- Join the discussion at local conferences such as the Myeloma Scientific Roundtable
- Sign up for updates from EasyM
Research Use.
Note that EasyM is seeking certification as a Laboratory Developed Test (LDT) by CLIA and by Health Canada. At present it can be used for research purposes and in a clinical trial for a novel therapeutic (or therapeutic application), but its results are not yet certified to be shared with patients or to direct clinical decisions.
If you’d like to receive our news and updates as we progress EasyM into a widely available clinical test, please follow us on LinkedIn and/or sign up below.